Morgan Stanley analyst Carlos De Alba maintains Ternium (NYSE:TX) with a Equal-Weight and lowers the price target from $48 to $39.
Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer’s 20-Plus-Year Near Monopoly, Says Analyst
Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention).
